Apellis Shares Are Trading Lower After the Company Announced the CHMP Has Adopted a Negative Opinion on the Marketing Authorization Application of Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy.
Apellis Shares Are Trading Lower After the Company Announced the CHMP Has Adopted a Negative Opinion on the Marketing Authorization Application of Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy.
Apellis股票下跌，因公司宣布欧盟CHMP对使用眼内注射Pegcetacoplan治疗地理萎缩症的市场授权申请做出负面意见。
Apellis Shares Are Trading Lower After the Company Announced the CHMP Has Adopted a Negative Opinion on the Marketing Authorization Application of Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy.
Apellis股票下跌，因公司宣布欧盟CHMP对使用眼内注射Pegcetacoplan治疗地理萎缩症的市场授权申请做出负面意见。